Drugs / Cal-Mag Butyrate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05367245 | Jan 2024 → Oct 2026 expected | cognitive disorder, myalgic encephalomeyelitis/chronic fatigue syndrome, persian gulf syndrome | VA Office of Research and Development | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cal-Mag Butyrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05367245 ↗ |
| Modality | Other / unclassified | “Butyrate, a nutraceutical endogenously produced in the host gut following bacterial fermentation” NCT05367245 ↗ |
| Route | Oral | “Take oral capsule as directed” NCT05367245 ↗ |